Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

IL-32α down-regulates β2 integrin (CD18) expression by suppressing PU.1 expression in myeloid cells.

Kang JW, Park YS, Kim MS, Lee DH, Bak Y, Ham SY, Song YS, Hong JT, Yoon DY.

Cell Signal. 2014 Jul;26(7):1514-22. doi: 10.1016/j.cellsig.2014.03.027. Epub 2014 Apr 2.

PMID:
24703937
2.

Intracellular interaction of interleukin (IL)-32α with protein kinase Cε (PKCε ) and STAT3 protein augments IL-6 production in THP-1 promonocytic cells.

Kang JW, Park YS, Lee DH, Kim JH, Kim MS, Bak Y, Hong J, Yoon DY.

J Biol Chem. 2012 Oct 12;287(42):35556-64. doi: 10.1074/jbc.M112.400911. Epub 2012 Aug 27.

3.

Interleukin (IL)-32β-mediated CCAAT/enhancer-binding protein α (C/EBPα) phosphorylation by protein kinase Cδ (PKCδ) abrogates the inhibitory effect of C/EBPα on IL-10 production.

Kang JW, Park YS, Kim MS, Lee DH, Bak Y, Ham SY, Park SH, Hong JT, Yoon DY.

J Biol Chem. 2013 Aug 16;288(33):23650-8. doi: 10.1074/jbc.M113.465575. Epub 2013 Jun 30.

4.

Interleukin-32α downregulates the activity of the B-cell CLL/lymphoma 6 protein by inhibiting protein kinase Cε-dependent SUMO-2 modification.

Park YS, Kang JW, Lee DH, Kim MS, Bak Y, Yang Y, Lee HG, Hong J, Yoon DY.

Oncotarget. 2014 Sep 30;5(18):8765-77.

5.
6.

IL-32θ inhibits monocytic differentiation of leukemia cells by attenuating expression of transcription factor PU.1.

Kim MS, Kang JW, Park YS, Lee DH, Bak Y, Kwon T, Yoon DY.

Oncotarget. 2015 Feb 28;6(6):4394-405.

7.

Signal transducers and activators of transcription 3 augments the transcriptional activity of CCAAT/enhancer-binding protein alpha in granulocyte colony-stimulating factor signaling pathway.

Numata A, Shimoda K, Kamezaki K, Haro T, Kakumitsu H, Shide K, Kato K, Miyamoto T, Yamashita Y, Oshima Y, Nakajima H, Iwama A, Aoki K, Takase K, Gondo H, Mano H, Harada M.

J Biol Chem. 2005 Apr 1;280(13):12621-9. Epub 2005 Jan 21.

8.

IL-32θ downregulates CCL5 expression through its interaction with PKCδ and STAT3.

Bak Y, Kang JW, Kim MS, Park YS, Kwon T, Kim S, Hong J, Yoon DY.

Cell Signal. 2014 Dec;26(12):3007-15. doi: 10.1016/j.cellsig.2014.09.015. Epub 2014 Oct 2.

PMID:
25280942
9.

Characterization and gene expression of transcription factors, PU.1 and C/EBPα driving transcription from the tumor necrosis factor α promoter in Japanese flounder, Paralichthys olivaceus.

Hikima J, Ohtani M, Kondo H, Hirono I, Jung TS, Aoki T.

Dev Comp Immunol. 2011 Mar;35(3):304-13. doi: 10.1016/j.dci.2010.10.003. Epub 2010 Oct 23.

PMID:
20951726
10.

Cooperation between PU.1 and CAAT/enhancer-binding protein beta is necessary to induce the expression of the MD-2 gene.

Tissières P, Araud T, Ochoda A, Drifte G, Dunn-Siegrist I, Pugin J.

J Biol Chem. 2009 Sep 25;284(39):26261-72. doi: 10.1074/jbc.M109.042580. Epub 2009 Jul 24.

11.

IL-32θ negatively regulates IL-1β production through its interaction with PKCδ and the inhibition of PU.1 phosphorylation.

Kim MS, Kang JW, Lee DH, Bak Y, Park YS, Song YS, Ham SY, Oh DK, Hong J, Yoon DY.

FEBS Lett. 2014 Aug 25;588(17):2822-9. doi: 10.1016/j.febslet.2014.06.029. Epub 2014 Jul 1.

12.

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations.

Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, Steffen B, Matsumura I, Kanakura Y, Böhmer FD, Müller-Tidow C, Berdel WE, Serve H.

Blood. 2003 Apr 15;101(8):3164-73. Epub 2002 Dec 5.

13.
14.

GABP and PU.1 compete for binding, yet cooperate to increase CD18 (beta 2 leukocyte integrin) transcription.

Rosmarin AG, Caprio DG, Kirsch DG, Handa H, Simkevich CP.

J Biol Chem. 1995 Oct 6;270(40):23627-33.

15.

Interleukin-32α modulates promyelocytic leukemia zinc finger gene activity by inhibiting protein kinase Cɛ-dependent sumoylation.

Park YS, Kang JW, Lee DH, Kim MS, Bak Y, Yang Y, Lee HG, Hong J, Yoon DY.

Int J Biochem Cell Biol. 2014 Oct;55:136-43. doi: 10.1016/j.biocel.2014.08.018. Epub 2014 Aug 29.

PMID:
25178676
16.

Granulocyte inducer C/EBPalpha inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions.

Reddy VA, Iwama A, Iotzova G, Schulz M, Elsasser A, Vangala RK, Tenen DG, Hiddemann W, Behre G.

Blood. 2002 Jul 15;100(2):483-90.

17.

Transcriptional control of Pactolus: evidence of a negative control region and comparison with its evolutionary paralogue, CD18 (beta2 integrin).

Hale JS, Dahlem TJ, Margraf RL, Debnath I, Weis JJ, Weis JH.

J Leukoc Biol. 2006 Aug;80(2):383-98. Epub 2006 May 30.

PMID:
16735694
19.
20.

BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.

Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, Iervolino A, Condorelli F, Gambacorti-Passerini C, Caligiuri MA, Calabretta B.

Nat Genet. 2002 Jan;30(1):48-58. Epub 2001 Dec 20.

PMID:
11753385

Supplemental Content

Support Center